Asset Details
Do you wish to reserve the book?
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
Do you wish to request the book?
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
2012
Overview
Aim To study the HER2 gene amplification or overexpression in patients with advanced gastric cancer (GC) and their association with patient characteristics and patient survival. Patients and methods Tumour tissue samples from 148 patients with advanced GC were studied for HER2 by immunohistochemistry (IHC), fluorescence in situ hybridisation (FISH) and dual colour silver enhanced in situ hybridisation (dc-SISH) methods. Clinicopathological data from all patients were collected. Progression free survival and overall survival were also analysed. Results Mean age was 67 (33–83) years; 75% were male subjects, and 51% had intestinal histological type. HER2+ rates were 10.1% (15/148) by IHC, 18.2% (27/148) by FISH+ or 21.6% (32/148) by dc-SISH+. There were significant differences in HER2+ rates according to histological type when FISH (intestinal, 23%; no intestinal, 4%; p<0.0001) or dc-SISH (intestinal, 26%; no intestinal, 6%; p<0.0001) amplification techniques were used. Median overall survival was significantly longer in HER2+ patients despite the determination technique used: IHC (21.4 vs 9.8 months, HR 0.42; p=0.005); FISH (19.6 vs 9.7 months, HR 0.49; p=0.007) or dc-SISH (19.6 vs 9.7 months, HR 0.53; p=0.009). Factors associated with favourable survival in the multivariate analysis were intestinal type and Her2+ determination by IHC, FISH or dc-SISH. Conclusion HER2 gene amplification is significantly associated with patient survival. HER2 gene amplification approaches might be an optimal HER2/neu testing strategy for the selection of HER2+ GC patients who are candidates to be treated with anti-HER2 therapies.
Publisher
BMJ Publishing Group Ltd and Association of Clinical Pathologists,BMJ Publishing Group,BMJ Publishing Group LTD,BMJ Group
Subject
/ Aged
/ Biological and medical sciences
/ CERB 2
/ Female
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ In Situ Hybridization, Fluorescence
/ Investigative techniques, diagnostic techniques (general aspects)
/ Male
/ Original
/ Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
/ pleura
/ Receptor, ErbB-2 - antagonists & inhibitors
/ Spain
/ Stomach Neoplasms - chemistry
/ Stomach Neoplasms - diagnosis
/ Stomach Neoplasms - genetics
/ Stomach Neoplasms - mortality
/ Stomach Neoplasms - secondary
/ Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
/ Studies
/ Tumors
